PPT-5-Year Clinical and Echocardiographic Outcomes from the Randomized SURTAVI Trial
Author : SocialButterfly | Published Date : 2022-08-02
Nicolas M Van Mieghem MD PhD For the SURTAVI Trial Investigators 0 Disclosure Statement of Financial Interests Within the past 12 months I have had a financial
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "5-Year Clinical and Echocardiographic Ou..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
5-Year Clinical and Echocardiographic Outcomes from the Randomized SURTAVI Trial: Transcript
Nicolas M Van Mieghem MD PhD For the SURTAVI Trial Investigators 0 Disclosure Statement of Financial Interests Within the past 12 months I have had a financial interestarrangement or affiliation with the organizations list below. A clinical evaluation to compare the safety efficacy and performance of the Absorb everolimuseluting bioresorbable vascular scaffold system against the XIENCE everolimuseluting coronary stent system in the treatment of subjects wit Daniel S Bennett MD DABPM. Denver, Colorado USA. “. Any tool is a weapon if you hold it right. ”. Ani. . Difranco. b. 1970. Case: Acute LLE L5 Radiculopathy. 3. 2. y HM (. Ht. 170.2cm, . Wt. 64.5kg. Everolimus. Eluting . Bioresorbable. Vascular Scaffold and the XIENCE . Everolimus. Eluting Stent. Bernard Chevalier. Institut Jacques Cartier, Massy, France. Patrick W. Serruys. Imperial College, London, UK. Susan S. . Ellenberg. , Ph.D.. University of Pennsylvania. SCT/ICTMC Joint Meeting. Liverpool, UK. May 8, 2017. CLINICAL TRIALS TIMELINE. 1948: First randomized clinical trials of modern era. 1962: Amendments to U.S. Food, Drug and Cosmetic Act requiring demonstration of efficacy as well as safety. Overview of Clinical Trials. : Phase I-III. Patricia . Mucci. . LoRusso,. D.O.. Associate Center Director – Innovative Medicine. Yale Cancer Center. <3% of all Cancer Patients Enroll in Clinical Trials. Everolimus. Eluting . Bioresorbable. Vascular Scaffold and the XIENCE . Everolimus. Eluting Stent. Bernard Chevalier. Institut Jacques Cartier, Massy, France. Patrick W. Serruys. Imperial College, London, UK. PROOF IN MEDICAL RESEARCH. Susan S. . Ellenberg. , Ph.D.. Department of Biostatistics and Epidemiology. Perelman School of Medicine, U Penn. Statistics is the science of uncertainty. Biostatistics is the application of statistics to biological problems. CLINICAL TRIALS IN THE TWENTY-FIRST CENTURY: ONGOING CHALLENGES AND EMERGING ISSUES Susan S. Ellenberg , Ph.D. University of Pennsylvania SCT/ICTMC Joint Meeting Liverpool, UK May 8, 2017 CLINICAL TRIALS TIMELINE WHAT IS A BIOSTATISTICIAN TRYING TO PROVE? PROOF IN MEDICAL RESEARCH Susan S. Ellenberg , Ph.D. Department of Biostatistics and Epidemiology Perelman School of Medicine, U Penn Statistics is the science of uncertainty Susan S. . Ellenberg. , Ph.D.. University of Pennsylvania. SCT/ICTMC Joint Meeting. Liverpool, UK. May 8, 2017. CLINICAL TRIALS TIMELINE. 1948: First randomized clinical trials of modern era. 1962: Amendments to U.S. Food, Drug and Cosmetic Act requiring demonstration of efficacy as well as safety. Wendy . Parulekar. MD, FRCP(C). Wei Tu PhD. Objectives. To review the classification of randomized phase II trial designs. To propose and critique potential randomized phase II trials designs for a concept in head and neck cancer (case scenario to be presented). Christopher B. Granger, MD. On behalf of the IMPACT-AF . Steering. Committee and Investigators. Background. AF is common (34 million people worldwide). AF is associated with a 5-fold increased risk of stroke. Junjing Lin. [Takeda], Margaret Gamalo [Pfizer], . Ram Tiwari. [BMS]. Expanding Real World Evidence in Pre-market Approvals. What Constitutes Externally Controlled Trials? . Potential Outcomes Framework. Low-risk Randomized Trial. Michael J. Mack, . MD & . Martin B. Leon, MD. on behalf of the PARTNER 3 Trial Investigators. Disclosures - Michael J. Mack, MD. ACC 2020; Chicago, IL; March 28–30, 2020.
Download Document
Here is the link to download the presentation.
"5-Year Clinical and Echocardiographic Outcomes from the Randomized SURTAVI Trial"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents
